COMP <GO>
AMRX vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Amneal Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AMRX 5
— ABBV 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: AMRX
LAST: $21.51 (+0.75%) • MKT CAP: $7.44B
options-implied-move
7.20%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMRX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMRX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.90% | 70.20% | -33.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.10% | 29.00% | -14.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.4x | 33.3x | -11.90 | AMRX | /valuation <GO> |
| Free Cash Flow Yield | 3.63% | 3.47% | +0.16 | AMRX | /fcf-yield <GO> |
| Operating Margin | 13.10% | 24.60% | -11.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 2.40% | 6.90% | -4.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 8.00% | 8.60% | -0.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.83 | 5.33 | -1.50 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 7.40% | -0.20 | AMRX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 72.8 | -5.13 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.0x | 113.1x | -17.10 | AMRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.44B | $513.86B | -$506.42B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMRX REV | ABBV REV | AMRX GROSS % | ABBV GROSS % | AMRX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.02B | $61.16B | 36.9% | 70.2% | $269.9M | $17.82B |
| FY 2024 | $2.79B | $56.33B | 36.5% | 70.0% | $243.2M | $17.83B |
| FY 2023 | $2.39B | $54.32B | 44.0% | 44.0% | $237.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMRX // BETA 1.08
ABBV // BETA 1.15